S-1/A: Tempus AI Files for IPO, Aiming to Revolutionize Precision Medicine with AI

Sentiment:

S-1/A Filing 5 June 2024 6:04 AM

Tempus AI, a healthcare technology company, has filed for an IPO to further its mission of transforming precision medicine through the application of artificial intelligence.

Capital raiseThe company is offering 11,100,000 shares of its Class A common stock in an initial public offering.The company has granted the underwriters the option to purchase up to an additional 1,665,000 shares of Class A common stock.The company intends to use approximately $74.5 million of the net proceeds from this offering to pay federal and state tax withholding and remittance obligations related to the RSU Net Settlement.The company currently intends to use the remaining net proceeds of this offering for general corporate purposes, including working capital, operating expenses, repayment of debt and capital expenditures.The company may also use a portion of the net proceeds to acquire complementary businesses, products, services or technologies.

Worse than expectedThe company's net losses increased from $54.4 million to $64.7 million in the three months ended March 31, 2023 and 2024, respectively.

Summary

Tempus AI, a technology company focused on healthcare, has filed for an IPO.
The company aims to revolutionize precision medicine by using AI to create Intelligent Diagnostics.
Tempus AI's platform combines a technology infrastructure with an operating system to make healthcare data useful.
The company has amassed a large library of clinical and molecular oncology data.
Tempus AI's platform connects multiple stakeholders in the healthcare ecosystem to enable data-driven decisions.
The company's product lines include Genomics, Data and Services, and AI Applications.
Tempus AI generated total revenue of $531.8 million in 2023 and $145.8 million in the three months ended March 31, 2024.
The company incurred net losses of $214.1 million in 2023 and $64.7 million in the three months ended March 31, 2024.
The company has assembled a world-class team of approximately 2,300 employees, including hundreds with diverse expertise.
The company intends to use approximately $74.5 million of the net proceeds from this offering to pay federal and state tax withholding and remittance obligations related to the RSU Net Settlement.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While it highlights the company's innovative approach and growth potential, it also acknowledges significant financial losses and risks associated with the business.

Positives

The company's platform has inherent network effects that help drive adoption and improve its data advantage.
The company's technology integration, go-to-market, and commercial infrastructure provide a significant strategic advantage.
The company's platform is disease agnostic and facilitates rapid expansion into different disease categories.
The company has a large repository of multimodal data that is essential for bringing AI to healthcare.
The company's Intelligent Diagnostics provide significant value to its customers, which has fostered broad adoption of many of its products.
The company's products and services are already widely used throughout the healthcare ecosystem.

Negatives

The company has incurred significant losses since inception and may continue to incur losses in the future.
The company's current or future products may not achieve or maintain sufficient commercial market acceptance.
The company's operating results may fluctuate significantly, which makes future operating results difficult to predict.
The company will need to raise additional capital to fund its existing operations, develop its platform, commercialize new products, or expand its operations.
The company's AI Applications product line is nascent.

Risks

The success of the company's business depends on its continued access to, and ability to monetize, de-identified patient data.
The company's limited operating history and rapid growth make it difficult to evaluate its future prospects.
If third-party payers do not provide coverage of, or adequate reimbursement for, the company's tests, its business will be negatively affected.
Failure of, or defects in, the company's platform's AI software could impair its ability to process data and harm its business.
If the company cannot compete successfully with its competitors, it may be unable to increase or sustain its revenue.
The company may acquire businesses or form joint ventures that could negatively affect its operating results.
The company relies on a limited number of suppliers for some of its laboratory instruments and materials.
The company conducts business in a heavily regulated industry, and changes in regulations may reduce its revenue.
If the company is unable to obtain, maintain, and enforce sufficient intellectual property protection, its competitors could develop similar products.
The company is highly dependent on the services of Eric Lefkofsky and other members of its senior management team.
The dual class structure of the company's common stock will concentrate voting control with its Chief Executive Officer, Founder and Chairman.
The company anticipates incurring substantial federal and state tax withholding and remittance obligations in connection with the settlement of RSUs that vest in connection with this offering.
The company's existing and any future debt may affect its flexibility in operating and developing its business.

Future Outlook

The company plans to continue investing in new assay development and expansion into new disease areas, and expects that research and development expenses will increase in absolute dollars for the foreseeable future.

Management Comments

We endeavor to unlock the true power of precision medicine by creating Intelligent Diagnostics through the practical application of artificial intelligence, or AI, in healthcare.
Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Our novel insight was realizing that all laboratory test results, genomic or otherwise, could be contextualized for a specific patient based upon that patients unique characteristics, and technology could therefore guide therapy selection and treatment decisions to allow each patient to progress on their own unique path.

Industry Context

The healthcare diagnostic and data industries are characterized by rapid changes, including technological and scientific breakthroughs, frequent new product introductions and enhancements and evolving industry standards, any of which could make our current and future products obsolete.

Comparison to Industry Standards

The company competes with diagnostics companies such as Foundation Medicine, Caris Life Sciences, Guardant Health, Neogenomics, and ResolutionBio.
The company also competes with healthcare technology companies providing data analysis products, including Flatiron Health, IQVIA Holdings Inc., and ConcertAI.
In cardiology, the company believes its competitors may include HeartFlow Inc., Anumana, Inc., and Eko Devices, Inc.

Legal Proceedings

On May 19, 2022, the company received a subpoena from the Office of the Ohio Attorney General.
On March 4, 2024, the company received a Civil Investigative Demand from the U.S. Attorneys Office for the Eastern District of New York.

Related Party Transactions

The company subleases a portion of office space to Lightbank LLC, Lefkofsky Family Foundation and 346 Investment Partners, each an entity affiliated with and controlled by Mr. Lefkofsky.
The company charters an aircraft for business use owned by 346 Investment Partners LLC, an entity affiliated with and controlled by Mr. Lefkofsky.
The company has a commercial relationship with Pathos AI, Inc., a healthcare company co-founded by Mr. Lefkofsky and Mr. Fukushima.
The company has a convertible promissory note with Google LLC.

Stakeholder Impact

The company's platform connects multiple stakeholders within the larger healthcare ecosystem, often in near real time, to assemble and integrate the data we collect, thereby providing an opportunity for physicians to make data-driven decisions in the clinic and for researchers to discover and develop therapeutics.
The company aims to help physicians find the best therapies for their patients, help pharmaceutical and biotechnology companies make the best drugs possible, and enable patients to access emerging therapies and clinical trials when appropriate.

Next Steps

The underwriters expect to deliver the shares of Class A common stock to purchasers on , 2024.
The company intends to use the net proceeds from this offering for general corporate purposes, including working capital, operating expenses, repayment of debt and capital expenditures.
The company may also use a portion of the net proceeds to acquire complementary businesses, products, services or technologies.

Key Dates

Date	Description
August 2015	Company originally formed under the name Bioin LLC in Delaware.
September 2015	Company converted to a Delaware corporation under the name Bioin Inc.
2015	Company changed its name to Tempus Health, Inc.
2016	Company changed its name to Tempus Labs, Inc.
2017	Company launched xT, 648 gene solid tumor cancer assay.
2018	Company launched xE, whole exome cancer assay and xF, 105 gene liquid biopsy cancer assay.
2019	Company launched xG, 52 gene inherited cancer risk germline assay and entered neuropsychiatry.
June 2019	Company launched TIME Trial program.
March 2020	Patient Protection and Affordable Care Act became law.
July 2020	Company launched iD test (COVID-19 PCR test).
September 2020	Company entered into a joint venture.
April 2021	Company launched xT-cdx, 648 gene, tumor/normal FDA approved assay.
May 2021	Company launched Lens, software application for life sciences and advanced precision research.
November 2021	Company entered into a Master Services Agreement with AstraZeneca AB.
January 2022	Company acquired Highline Consulting, LLC.
October 2022	Company acquired Arterys, Inc.
January 2023	New CPT code went into effect covering full transcriptome testing when performed separately from DNA testing.
First Quarter 2023	Company stopped offering COVID-19 PCR diagnostic tests.
April 2023	Company received FDA approval for xT CDX assay.
October 2023	Company received approval on xT assay from MolDx and launched xF+, expanded 523 gene panel.
November 2023	Company entered into a Commercialization and Reference Laboratory Agreement with Personalis, Inc. and entered into a Master Agreement with Recursion Pharmaceuticals, Inc.
March 2024	Company received approval on xF assay from MolDx.
April 2024	Company issued and sold 3,489,981 shares of Series G-5 convertible preferred stock.
May 18, 2024	Company entered into a Joint Venture Agreement with SoftBank Group Corporation.
June 1, 2024	Company launched xM high coverage methylation sequencing assay for minimal residual disease detection.

Keywords

precision medicine, artificial intelligence, AI, genomics, diagnostics, healthcare, data, clinical trials, NGS, oncology

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.